Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394266 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2621334 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL3390883 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL183857 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1521506 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854359 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL30854351 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1671746 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL342905 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL9961490 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903386-A | Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition | 厦门碳控科技投资有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | ISOTHRIVE LLC | 2024-02-08 | — | — | US | claimed |
| EP-4314332-A2 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| EP-3166615-B1 | CHELATED PHOSPHOROTIOTATED NUCLEIC ACID POLYMERS FOR USE IN COMBINATION WITH A HBV POLYMERASE INHIBITOR FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D VIRUS INFECTIONS | REPLICOR INC (CA) | 2023-08-09 | — | — | EP | claimed |
| EP-3047023-B1 | COMPOSITIONS AND METHODS FOR INHIBITING JC VIRUS (JCV) | US HEALTH (US) | 2019-09-04 | — | — | EP | claimed |
| CN-110121562-A | Method of producing a composite material | 牛津纳米孔技术公司 | 2019-08-13 | — | — | CN | claimed |
| CN-109206464-A | A kind of adenosine diphosphate core saccharide compound and preparation method thereof and bioactivity | 北京大学 | 2019-01-15 | — | — | CN | claimed |
| CN-108866058-A | It targets the siRNA of KRAS and its is preparing the application in treatment of pancreatic cancer drug | 苏州吉玛基因股份有限公司 | 2018-11-23 | — | — | CN | claimed |
| US-10036020-B2 | Compositions and methods for inhibiting JC virus (JCV) | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2018-07-31 | — | — | US | claimed |
| US-9994856-B2 | Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein | PROQR THERAPEUTICS II B.V. (NL) | 2018-06-12 | — | — | US | claimed |
| US-6423867-B1 | FROM TRI-O-ACETYL-D-ERYTHRO-4-PENTULOSONIC ACID ESTERS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2002-07-23 | — | — | US | claimed |
| US-20020026071-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES, OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-28 | — | — | US | claimed |
| US-20020026073-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-28 | — | — | US | claimed |
| US-20020026072-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2002-02-28 | — | — | US | claimed |
| US-20020026074-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERS | 2002-02-28 | — | — | US | claimed |
| US-20020019542-A1 | Process and intermediate compounds for the preparation of pyrrolidines | MICHIGAN STATE UNIVERSITY BOARD OF TRUSTEES OPERATING | 2002-02-14 | — | — | US | claimed |
| US-20020019561-A1 | Process and intermediate compounds for the preparation of pyrrolidines | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2002-02-14 | — | — | US | claimed |
| WO-2002010130-A1 | PROCESS AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF PYRROLIDINES | MICHIGAN STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026073-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20020026071-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20020019542-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20020026074-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20020026072-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20020019561-A1 | Process and intermediate compounds for the preparation of pyrrolidines | UMPS, DUT, DPYD | PDE4A 935/4885LMNA 2986/4885L3MBTL1 4143/4885 |
| US-20240041944-A1 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | DDOST, STT3A, SI | PDE4A 2526/4885LMNA 689/4885L3MBTL1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.